KI-Beratung Beta

Produktbild: Do Pharmaceutical Mergers Harm Drug Innovation?
Band 1197

Do Pharmaceutical Mergers Harm Drug Innovation?

27,95 €

inkl. gesetzl. MwSt., zzgl. Versandkosten


  • Kostenlose Lieferung ab 30 € Einkaufswert
  • Versandkostenfrei für Bonuscard-Kund*innen

Beschreibung

Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions...

Beschreibung

Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation.Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

12.06.2015

Abbildungen

1 Farbabb.

Verlag GRIN

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

12.06.2015

Abbildungen

1 Farbabb.

Verlag GRIN
Seitenzahl

56

Maße (L/B/H)

21/14,8/0,5 cm

Gewicht

96 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-3-656-96217-5

Herstelleradresse


Email: info@bod.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Do Pharmaceutical Mergers Harm Drug Innovation?